

(12)

**EUROPEAN PATENT APPLICATION**

(21) Application number: 86309305.0

(51) Int. Cl.<sup>4</sup>: **A 61 K 9/48**  
**A 61 K 47/00**

(22) Date of filing: 28.11.86

(30) Priority: 29.11.85 IL 77186

(43) Date of publication of application:  
10.06.87 Bulletin 87/24

(84) Designated Contracting States:  
AT BE CH DE ES FR GB GR IT LI LU NL SE

(71) Applicant: **R.P. SCHERER CORPORATION**  
**West Big Beaver Road**  
**Troy Michigan 48064(US)**

(72) Inventor: **Davies, John Desmond**  
**30, Newberry Place**  
**Grossepointe Farms Michigan 48236(US)**

(72) Inventor: **Toultou, Elka**  
**54, Kubovl Street**  
**Jerusalem(IL)**

(72) Inventor: **Rubinstein, Arnold**  
**123, Mishmar Hayarden Street**  
**Tel Aviv(IL)**

(74) Representative: **Coleiro, Raymond et al,**  
**MEWBURN ELLIS & CO. 2/3 Cursitor Street**  
**London EC4A 1BQ(GB)**

(54) Targeted enteral delivery system.

(57) A capsule for oral administration of a pharmaceutically active ingredient contains a pharmaceutical composition comprising the active ingredient, for example, a peptide, an absorption promoter and usually, a carrier. The absorption promoter is capable of enhancing absorption of the active ingredient from the intestine into the bloodstream. The capsule is coated with a film forming composition, which film is sufficiently insoluble at a pH below 7 as to be capable of protecting the capsule and its contents from the digestive juices until the capsule reaches a region below the upper part of the intestine, whereupon the coating and capsule are capable of eroding or dissolving to release the active ingredient for absorption into the bloodstream.

TARGETED ENTERAL DELIVERY SYSTEM

This invention relates to a targeted enteral delivery system which enables a medicament to be released at a region of the intestine such as the colon at which  
5 the medicament is not significantly adversely affected by digestive juices.

Certain drugs such as insulin and other proteins or peptides if administered orally to a patient and allowed to pass unprotected through the stomach, exhibit  
10 poor efficacy.

For example, the poor efficacy of orally administered insulin in diabetic patients is mainly due to two properties of this substance:

- (a) insulin is a pancreatic hormone peptide and thus  
15 subject to proteolytic inactivation during the passage through the gastro-intestinal tract, mainly in its upper region;
- (b) insulin has a high tendency for self-association to form high molecular weight oligomers and as a result  
20 of this increase in molecular weight the amount of insulin passing through enteral membranes by diffusion is not sufficient to achieve appreciable therapeutic effects.

It has been shown by coinventors of the present  
25 invention (Touitou et al., J. Pharm. Pharmacol. (1980),

32, 108-110) that significant hypoglycaemia can be induced in rats when insulin is injected intrajejunally in the presence of a non-ionic surfactant, Cetamacrogol<sup>TM</sup><sub>1000</sub>, as absorption promoter. They  
5 suggested that insulin absorption might be accomplished by oral administration of a suitably designed product containing insulin and surfactant provided that the insulin were protected against degradation by a suitable coating during its passage to the jejunal absorption  
10 site.

US-4406896 and US-4464363 describe rectally administered drug forms which include, in addition to the drug, an absorption promoter such as 5-methoxysalicylic acid for enhancing absorption of the drug into the blood-  
15 stream from the rectum.

Such rectal administration is, however, inconvenient to the patient.

GB-B-2123695 describes orally administrable dosage forms consisting of a tablet or capsule containing  
20 5-amino-salicylic acid for local treatment of colonic or rectal disorders. The dosage form is coated with a 60 to 150 micron thick layer of Eudragit S - a commercially available anionic polymer which is a partly methyl esterified methacrylic acid polymer ("Eudragit" is a  
25 trade mark). The coating is insoluble in the gastric and

intestinal juices below pH 7 but soluble in colonic juices, so that the oral dosage form remains intact until it reaches the colon.

US-A-4432966 describes compressed tablets for  
5 disintegration in the colon, which tablets contain active ingredients such as neomycin and prednisolone. The tablets are provided with a double coating, the inner of which contains microcrystalline cellulose and a film-forming polymer which is not degraded by a neutral or  
10 alkaline medium, and the outer of which is a pharmaceutically acceptable enteric coating.

However, such compositions have not been designed to allow significant amounts of active ingredient to be absorbed into the bloodstream.

15 Thus, although highly desirable from a practical point of view, unit dosage forms for the oral administration of drugs such as insulin, which drugs are susceptible to attack by the digestive juices, have not, to date, been successful.

20 The problem therefore is both to protect drugs such as peptides from proteolysis and to achieve useful absorption from the colon into the bloodstream. We have found a delivery system of a coated capsule with certain substances in the capsule contents which leads to an  
25 enhancement of absorption from the intestine.

This delivery system results in a decrease in drug inactivation and an increase in drug absorption.

The invention provides a capsule for oral administration of a pharmaceutically active ingredient (hereinafter "drug") which capsule contains a pharmaceutical composition, which composition comprises the drug, an absorption promoter capable of enhancing absorption of the drug from the intestine into the bloodstream, and, if appropriate, a suitable pharmaceutically acceptable excipient, and which capsule is coated with a film forming composition, which film is sufficiently insoluble at a pH below 7 as to be capable of protecting the capsule and its contents from the digestive juices until the capsule reaches a region in which the active ingredient will not be significantly adversely affected by the digestive juices, whereupon the coating and capsule are capable of eroding or dissolving so as to release the drug for absorption into the bloodstream.

A targeted enteral delivery system in accordance with the invention is especially applicable to any drug which (i) is poorly absorbed, and/or (ii) is degraded by the gastric or small-intestinal juices, and/or (iii) induces side effects in the stomach/small intestine, but is particularly useful for administration of

therapeutically useful peptide or protein drugs, for example insulin, gastrin, pentagastrin, calcitonin, human growth hormone, glucagon, adrenocorticotrophic hormone, leutinising releasing hormone, enkephalin, oxycotin, 5 parathyroid hormone, thyrotropic releasing hormone and vasopressin.

The capsules are adapted to effectively release the drug at any region within the lower part of the gastro-intestinal tract, where proteolysis is rather low. 10 Such release may occur at any region below the upper part of the small intestine, including the lower part of the small intestine, and including the rectum. However, preferred capsules release the drug in the jejunum or colon, especially the colon.

15 A particularly preferred dosage form is one comprising insulin contained in gelatin capsules coated with a suitable polymer, such as a polyacrylic polymer which has pH dependent properties.

The capsule may be a soft or hard gelatin 20 capsule.

A soft gelatin capsule shell is preferably prepared from a capsule composition comprising gelatin, or a substituted gelatin, e.g. phthallated or succinated gelatin, and a plasticiser such as a polyhydric alcohol, 25 e.g. glycerol. For specific cases, a blend of polyhydric

alcohols, or a blend of one or more polyhydric alcohols with other plasticisers is preferred, for example, a blend of glycerol with a sorbitol solution or a blend of glycerol with a sorbitol/sorbitan mixture.

5           The soft gelatin capsule compositions additionally include water (which is evaporated off on drying) and may additionally include other additives such as opacifiers, e.g. silicone oil, preservatives, e.g. potassium sorbate and colours.

10           The soft gelatin capsule shell composition (before drying) preferably comprises 30-53 parts gelatin or substituted gelatin, 15-48 parts plasticiser and 16-40 parts water, the parts being by weight of the total weight of the composition.

15           In the dried capsule, the gelatin or substituted gelatin usually amounts to 40-70% and the plasticiser to 10-50% by weight of the total weight of the composition.

A typical soft gelatin capsule composition (after drying) comprises essentially

20	Gelatin	57.65% w/w
	Glycerin	28.95% w/w
	Silicone Oil	13.14% w/w
	Potassium Sorbate	0.26% w/w

A hard gelatin capsule shell is preferably  
25 prepared from a capsule composition comprising gelatin

and a small amount of plasticiser such as glycerol.

As an alternative to gelatin, the capsule shell may be made of a carbohydrate material.

The capsule composition may additionally include  
5 colourings, flavourings and opacifiers as required.

The absorption promoter of a pharmaceutical composition present in a capsule in accordance with the invention is preferably an organic aromatic carboxylic acid or ester or amide thereof. Examples are salicylic  
10 acid and salicylates such as 5-methoxysalicylic acid; 5-methylsalicylic acid; 3-methylsalicylic acid; 5-tert-octylsalicylic acid; 3-tert-butyl-6-methylsalicylic acid; 3,5-diisopropylsalicylic acid; 3-tert-butyl-5-methylsalicylic acid; 5-bromosalicylic acid; 3,5-  
15 diiodosalicylic acid; 3-methoxysalicylic acid; 5-octyloxysalicylic acid; 5-butoxysalicylic acid; 5-chlorosalicylic acid; and the sodium salts thereof.

Other examples are homovanillic acid; 2,5-dihydroxybenzoic acid; 2,4-dihydroxybenzoic acid; 5-  
20 methoxy-2-hydroxyphenylsulfonic acid; guaicol-sulfonic acid; 2-hydroxyphenylacetic acid; 2-hydroxyphenylmethanesulfonic acid; 5-trifluoromethyl-2-hydroxybenzoic acid; 2-hydroxy-3-methoxybenzoic acid; and the sodium salts thereof.

25 Other useful absorption promoters are surface



active agents such as a mixture of a) a higher fatty acid salt and b) a fatty alcohol or glyceride. The glyceride may be a mono- or di-glyceride.

A preferred surface active agent is a mixture of  
5 sodium laurate with cetyl alcohol, stearyl alcohol, glyceryl monostearate or glyceryl monocaproate, especially a sodium laurate/cetyl alcohol mixture.

The choice of absorption promoter depends upon the drug and promoters which enhance absorption of  
10 peptides or proteins such as insulin, pentagastrin and gastrin with particularly excellent effects are 5-methoxysalicylic acid; salicylic acid; 2,5-dihydroxybenzoic acid; 2,4-dihydroxybenzoic acid; 3-methylsalicylic acid; 5-methylsalicylic acid; 5-tert-octylsalicylic acid; 3-tert-butyl-6-methylsalicylic acid;  
15 3,5-diisopropylsalicylic acid; 3-tert-butyl-5-methylsalicylic acid; 5-bromosalicylic acid; 3,5-dibromosalicylic acid; 5-iodosalicylic acid; 3,5-diiodosalicylic acid; 2-hydroxy-phenylacetic acid; 5-trifluoromethyl-2-hydroxybenzoic acid; 3-methoxysalicylic  
20 acid; 5-octyloxysalicylic acid; 5-butoxy-salicylic acid; 5-chlorosalicylic acid; 2-hydroxy-3-methoxybenzoic acid; and the sodium salts thereof.

Good absorption of insulin is also achieved using  
25 a sodium laurate/cetyl alcohol (1:4) surfactant mixture.

Promoters which enhance the absorption of  $\beta$ -lactam antibiotic drugs such as penicillin G, ampicillin, amoxicillin, methacillin, carbenicillin, cefoxitin, cephamandole, cephaprin, cephradine, 5 cephanone, oxacephalosporin, and N-formimidoyl thienamycin with particularly excellent effects are 5-methoxy-salicylic acid; salicylic acid; homovanillic acid; 2,5-dihydroxybenzoic acid; 2,4-dihydroxybenzoic acid; 5-methoxy-2-hydroxyphenylsulfonic acid; 3-10 methylsalicylic acid; 5-methylsalicylic acid; 5-tert-octylsalicylic acid; 3-tert-butyl-6-methylsalicylic acid; 3,5-diisopropylsalicylic acid; 3-tert-butyl-5-methylsalicylic acid; guaicol-sulfonic acid; 5-bromosalicylic acid; 3,5-dibromosalicylic acid; 5-15 iodosalicylic acid, 3,5-diiodosalicylic acid; 2-hydroxyphenylacetic acid; 2-hydroxyphenylmethanesulfonic acid; 5-trifluoromethyl-1-hydroxybenzoic acid; 3-methoxy-salicylic acid; 5-octyloxysalicylic acid; 5-butoxy-salicylic acid; 3,4-dihydroxyphenylacetic acid; 5-20 chlorosalicylic acid; 2-hydroxy-3-methoxybenzoic acid; salicyluric acid; and the sodium salts thereof.

Generally the amount of absorption promoter in our drug forms is from 1-1000 mg in each unit dose. The percentage of absorption promoter in the total 25 combination of drug plus absorption promoter is usually

20-95% with a preferred ratio of promoter in the total combination of promoter plus drug being 30-60%. A most preferred ratio of promoter to promoter plus drug is 50%.

In addition to the drug and absorption promoter, the pharmaceutical composition usually includes a carrier such as polyethylene glycol having a molecular weight of from 400-5000, preferably from 600-4000, and more preferably a mixture of a solid polyethylene glycol having a molecular weight of, say, 4000 and a liquid polyethylene glycol having a molecular weight of, say, 600, or an oil, for example, soya bean oil, arachis oil, or an ester of a medium chain fatty acid, for example a triglyceride of fractionated coconut oil  $C_{8-10}$  fatty acids, e.g. a caprylic/capric triglyceride mixture optionally including a small amount, say 5%, linoleic acid, or a propylene glycol diester of saturated  $C_{8-10}$  fatty acids e.g. a propylene dicaprylate/dicaprate mixture.

The coating composition is preferably an anionic copolymer of methacrylic acid and a methacrylic acid ester, such copolymers being commercially available under the trade name "Eudragit" (TM). Eudragit may be used in a variety of forms. Such a copolymer, or more preferably a mixture of such copolymers, may also be admixed with a further film-forming component such as ethyl cellulose (available under the trade name "Ethocel") or shellac.

Typical methacrylic acid/methacrylate copolymers are:

Eudragit RS - a copolymer derived from acrylic and methacrylic acid esters with a low content of  
5 quaternary ammonium groups. The molar ratio of these ammonium groups to the remaining neutral (meth)acrylic acid esters is 1:40. The mean molecular weight of the copolymer is approximately 150,000.

Eudragit S - an anionic copolymer derived from  
10 methacrylic acid and methyl methacrylate. The ratio of free carboxyl groups to the esters is approximately 1:2. The mean molecular weight of the copolymer is approximately 135,000.

Eudragit L - an anionic copolymer derived from  
15 methacrylic acid and methyl methacrylate. The ratio of free carboxyl groups to the ester groups is approximately 1:1. The mean molecular weight of the copolymer is approximately 135,000.

Various forms of Eudragit were examined for  
20 various delivery systems and amongst satisfactory systems there may be mentioned soft gelatin capsules filled with a quantity of the order of 100 mg containing 8 iu porcine insulin, 20 mg of surfactant mixture (sodium laurate: cetyl alcohol 1:4) in arachis oil. The capsules were  
25 coated with various mixtures of Eudragit RS, L and S.

The in-vitro pH dependent release rates of coated capsules were tested by scintillation counting using  $^{125}\text{I}$ -insulin. Two dosage forms including respective coating compositions which gave best results as regards release at a pH in the 7.5 to 8.0 range (RS1 and RS2) were chosen for further studies with rats. Such capsules were administered to male rats (270 g) and insulin absorption was measured by the determination of the resulting hypoglycaemic effect. The oral administration of the two dosage forms of choice gave a significant ( $p < 0.01$ ) hypoglycaemia when compared with controls. Duration, course and intensity of effect were different for each of the tested formulations, as will be shown in detail hereinafter. The pre-administration of a capsule containing a surfactant did not change the glycaemic profile; the post-administration prolonged the effect of RS2 from 1 to 2 hours.

Embodiments of the invention will now be described in more detail with reference to the following Examples and accompanying drawings which are explained later in a legend.

Examples of Pharmaceutical compositions for insertion  
into gelatin capsules

Examples 1-3

Three formulations, based on polyethylene glycol and  
5 containing the peptide drugs insulin, calcitonin and  
human growth hormone respectively, for encapsulation in  
capsules embodying the invention are as follows.

	Example 1	Example 2	Example 3
Ingredient	Insulin	Calcitonin (Pork)	Human Growth Hormone
Peptide	20 i.u. (ca.1mg)	80 i.u. (ca.1mg)	4 i.u. (ca.2mg)
15 Sodium 5-methoxy salicylate (1)	150.0mg	150.0mg	150.0mg
PEG 4000 (2)	3.5mg	3.5mg	3.5mg
PEG 600 (3)	187.5mg	187.5mg	186.5mg
Capsule fill wt	342 mg	342 mg	342 mg

(1) absorption promoter

(2) polyethylene glycol having a molecular  
weight of 4000 - a solid thickener  
which increases viscosity and allows  
25 suspension of solid particles.

(3) polyethylene glycol having a molecular weight of 600 - a liquid suspending agent.

5 The quantities of each ingredient may be varied from the above for other drugs to obtain optimum formulations and therapeutic efficacy.

The above formulations are designed to be accommodated into a hard or a soft gelatin capsule.

10 Where the above formulations are encapsulated within soft gelatin capsules the shell comprises

Gelatin	57.65% w/w
Glycerin	28.95% w/w
Silicone Oil	13.14% w/w
Potassium Sorbate(preservative)	0.26% w/w

15 Examples 4 - 6

Three oil based formulations containing the peptide drugs insulin, calcitonin and human growth hormone respectively, for encapsulation in capsules embodying the invention are as follows.

Ingredient	Example 4	Example 5	Example 6
	Insulin	Calcitonin (Pork)	Human Growth Hormone
5 Peptide	20 i.u. (ca.1mg)	80 i.u. (ca.1mg)	4 i.u. (ca.2mg)
Sodium 5-methoxy salicylate (1)	150.0mg	150.0mg	150.0mg
Fat Mix (5)	15.0mg	15.0mg	15.0mg
10 Soya lecithin (2)	3.0mg	3.0mg	3.0mg
Tween(TM) 80 (3)	7.5mg	7.5mg	7.5mg
Miglyol(TM) 812(4)	123.5mg	123.5mg	122.5mg
15 Capsule fill wt.	300.0mg	300.0mg	300.0mg

- (1) absorption promoter
- (2) wetting agent
- 20 (3) a 20-mole oxyethylated sorbitan monooleate  
surfactant
- (4) A triglyceride of a fractionated coconut oil  
C<sub>8-10</sub> fatty acids (mainly caprylic and capric), as  
suspension medium
- 25 (5) thickener



The above formulations are encapsulated within hard gelatin capsules, or within soft gelatin capsules of the shell formulation given for Examples 1-3.

Examples 7-9

- 5 Three oil based formulations similar to those of Examples 4-6 but containing larger concentrations of surfactant are as follows.

	Example 7	Example 8	Example 9
Ingredient	Insulin	Calcitonin	Human Growth
10		(Pork)	Hormone
	Peptide	Peptide	Peptide
	20 i.u. (ca.1mg)	80 i.u. (ca.1mg)	4 i.u. (ca.2mg)
15	Sodium 5-methoxy salicylate	150.0mg	150.0mg
	Fat Mix	15.0mg	15.0mg
	Soya lecithin	3.0mg	3.0mg
	Tween 80	45.0mg	45.0mg
	Miglyol 812	86.0mg	85.0mg
20			
	Capsule fill wt.300.0mg	300.0mg	300.0mg

The above formulations of Examples 7 - 9 are designed to be accommodated into soft or hard gelatin capsules, for example, soft gelatin capsules of the shell

formulation given in Examples 1 - 3. Formulations containing high surfactant concentrations (Examples 7-9) may promote self-emulsification of the capsule contents in an aqueous medium. Furthermore at such high concentrations, the surfactant will additionally assist in absorption promotion.

In each formulation type, the quantities of each ingredient may be varied for a given drug to obtain optimum formulations and therapeutic efficacy. The choice of a surfactant is not restricted to Tween 80; other surfactants satisfying regulatory and performance requirements may alternatively be employed.

#### Examples of capsules embodying the invention

The drugs and additives used for the dosage form formulations were: porcine insulin Leo Neutral 100 iu ml<sup>-1</sup> (Nordisk Gentofte, Denmark) and <sup>125</sup>I porcine insulin (NEN) with a specific activity of 99μCi μg<sup>-1</sup> and a radiochemical purity of 98%. Sodium laurate and cetyl alcohol (Sigma) were "chemically pure" substances and arachis oil conformed to the B.P. requirements.

#### Dosage Form Design :

The oral dosage form design was based on the incorporation of an insulin formulation into soft gelatin capsules coated with polyacrylic polymer - Eudragit (TM) (Rohm Pharma, Germany) - having pH-dependent solubility

properties. The soft capsules were filled with various compositions according to their use during the experiment. The compositions are presented in Table 1. Organic solvent solutions of Eudragit RS, L and S at various ratios were used to coat the capsules (Table 2).  
Preparation of the Formulation (Table 1)

800  $\mu$ l of porcine insulin solution (Leo Neutral) was mixed with 40 mg sodium laurate and 160 mg cetyl alcohol (small pieces) and was heated to 40°C. The arachis oil was added to obtain 1000 mg preparations. Soft gelatin capsules containing arachis oil were emptied using a syringe and filled with the active preparation. The whole was closed with melted gelatin.

In Vitro Insulin Release Measurements :

The coating effectiveness was tested in vitro using the USP disintegration apparatus USP XIX, 1975. The release media used were artificial gastric juice (60 ml N HCl per litre) and buffer phosphate solutions of respective pH's 6.0, 6.5, 7.0, 7.5 and 8.0. In each experiment six capsules were tested for 1 hour in gastric juice, briefly rinsed with distilled water and transferred to a phosphate buffer solution.

The in vitro pH-dependent release course was tested by scintillation counting using  $^{125}\text{I}$  insulin diluted with cold insulin (Table 1), the USP dissolution

detected at pH 8.0; whereas at pH 7.5, the release process was instantaneous. These release properties of RS1 and RS2 are convenient for the colon content milieu. Moreover, their choice was based on the release behaviour in a wide pH range (6 to 8) as presented in Figure 2.

The pH-dependent release courses indicate that formulations RS1 and RS2 do not release detectable amounts of insulin at a pH lower than pH 7. The other formulations tested, RS, RS3 and LS, release considerable amounts of drug at pH 6.5 and pH 7.0 corresponding to upper-intestinal regions. These formulations were considered unsuitable for our purpose even though their release rates at pH's 7.5 and 8.0 were higher than that of the chosen formulations RS1 and RS2 (Figure 2).

The selected capsules were administered to rats following the protocol presented in Scheme 1, and the results were compared with those obtained by intra-peritoneal administration of 4 iu neutral insulin.

The mean of the blood glucose concentration of the samples prior to dosage administration was used as a baseline for plotting the response versus time curves. Figure 3 presents the changes in blood glucose concentration that occurred after oral and intra-peritoneal treatment. It is interesting to note the lag time of two hours that occurred for each insulin oral

regime tested. The effect of RS2 is higher (45% reduction in glycaemia) but shorter (it lasted for about one hour) than RS1.

It was suggested that one of the causes of the short duration of enteral administration of insulin with promoter may reside in a difference in the absorption rate, from the intestinal tract, of insulin and promoter. To test this hypothesis, capsules containing only the surfactant were administered, in one trial before and in one trial after insulin administration. No change was observed by pre-treatment. However, the surfactant given 30 minutes post-insulin oral treatment extended the duration of RS2 by about one hour, improving the drug bioavailability. Similar results have been obtained by Nishihata et al, J. Pharm, Pharmacol. (1985), 37, 22-26, who reported that post-administration of promoter (enamine) in rectal dosage of insulin in dogs improved the bioavailability from 19.4% to 38.2%.

Curves of % glucose and % glucose reduction versus time were plotted (see Figures 3 and 4) and the area under the % glucose reduction versus time curve (AUC), the maximum glucose reduction ( $C_{max}$ ) and the time of the maximum effect ( $t_{max}$ ) were estimated from these curves. Their values are given in Table 3.

A schematic comparison of the AUC of orally administered

basket and 400 ml phosphate buffer solution. Each value given is the mean of 3 experiments.

Animal Experimental Design :

Results obtained by direction of insulin into  
5 selected regions of the gastro-intestinal lumen suggested that it would be worthwhile to investigate the effectiveness of oral dosage forms designed to deliver insulin in the presence of an absorption promoter in that part of the intestine where the proteolysis is relatively  
10 low.

The rationale of choosing gelatin capsules as dosage forms is based on the wide formulation possibilities offered by this form: 1) incorporation of oily compositions in which insulin and promoter are  
15 molecularly dispersed, 2) coating for targeting the drug release into the colon.

Hebrew University strain male rats (270 g) were starved for 20 hours before the experiment. During the experiment the rats received water ad libitum. The  
20 capsules were administered to the rats according to the study design presented in Scheme 1. The absorption of the intact insulin was evaluated by measuring the hypoglycaemic effect. Blood was collected from the rats' tails immediately before capsule administration and at  $\frac{1}{2}$ ,  
25 1, 2, 3, 4 and 6 hours afterwards. The rats were ether-

Scheme 1

<u>No. of rats</u>		<u>No. of caps. administered per rat</u>		
		Caps. Ins.	Caps. Ins.	Caps. Surf.
		(RS1)	(RS2)	(RS2)
5	5	2	-	-
	5	-	2	-
	5	-	2	1*
	5	-	2	1**
	4	-	-	2

- 10 Given 30 minutes \* after \*\* before insulin capsules' administration.

The above insulin capsules all contain the formulation referred to as Caps. Ins. 2 in Table 1, which includes surfactant.

insulin (RS2) and intraperitoneally administered insulin clearly indicates that the oral preparation is effective, but its bioavailability is relatively low. The  $C_{max}$  obtained with formulation RS2 (p 0.01) and the  
 5 prolongation effect of post-administration of promoter are worth noting.

Table 1 Composition for soft gelatin capsules

10	<u>Materials</u>	<u>Caps.Ins.1</u> <sup>*</sup>	<u>Caps.Ins.2</u> <sup>**</sup>	<u>Caps Surf</u> <sup>**</sup>
	Porcine insulin	8 iu	8 iu	-
	<sup>125</sup> I insulin (porcine)	5 $\mu$ Ci	-	-
	Sodium laurate	4 mg	4 mg	4 mg
15	Cetyl alcohol	16 mg	16 mg	16 mg
	Arachis oil to	100 mg	100 mg	100 mg

\* tested in vitro

\*\*administered in vivo

- 20 Caps. Ins.1 - capsules containing labelled insulin, insulin diluent and surfactant.
- Caps. Ins.2 - capsules containing insulin, diluent and surfactant.
- Caps. Surf. - capsules containing no insulin but containing surfactant.



Table 3      Some pharmacokinetic parameters related to  
the hypoglycaemic effect in rats of insulin  
upon oral administration of soft capsules  
coated with Eudragit compared with  
intraperitoneal administration.

5

<u>Treatment</u>		<u>Loading dose</u>	<u>Dose</u>	<u>AUC</u>	<u>C<sub>max</sub></u>	<u>t<sub>max</sub></u>
		iu	iu kg <sup>-1</sup>		% glucose reduction	hr.
	i.p.	4	15	258	58	2
10	p.o. RS1	16	59	110	45	3
	RS2	16	59	96	32	3
	RS2+Surf	16	59	131	42	3

15    i.p. intra-peritoneal  
p.o. oral

Table 2 The Eudragit RS, S and L ratios used for coating the capsules\*

<u>Formulation</u>		<u>Eudragit</u>		
		RS	S	L
5	RS	2	-	8
	RS1	4	6	-
	RS2	2	2	6
	RS3	1	-	9
	LS	-	7	3

10

\* solvents: acetone and isopropyl alcohol

coated capsules as compared with  
intraperitoneal administration of 4 iu  
insulin.

5 The use of a coating, such as a Eudragit coating,  
especially a Eudragit RS1 or RS2 coating as described  
above on a gelatin capsule with a pharmaceutical  
composition containing an absorption promoter within the  
capsule provides an excellent delivery system enabling  
oral administration of a drug which until now could only  
be administered by injection.

Legend

Figure 1. Release profiles of insulin from capsules coated with Eudragit mixtures tested at pH 7.5 and pH 8. Formulations:

5           ○ RS1           □ RS2

Figure 2 Effect of pH on the release rate of insulin from soft capsules coated with various mixtures of Eudragit S, L and RS (see description of Fig. 3 below).

10

Figure 3 Hypoglycemic effect of insulin administered orally to normal rats by means of coated soft capsules containing an absorption enhancing formulation (for formulations see Table 1)

15

Symbols for Figures 2 and 3:

☆ 2 capsules RS1, ○ 2 capsules RS2,

□ 2 capsules RS2 + 1 capsule surfactant post-insulin administration,

20

● insulin i.p. 4 iu, ★ 2 capsules surfactant (no insulin). Each point is the mean  $\pm$  SD of 5 animals for insulin administration and of 4 animals for controls.

Figure 4. Area under the curve (AUC) of the % blood glucose reduction versus time (hr.) profile upon oral administration of 16 iu insulin in

25

human growth hormone, glucagon, adrenocorticotrophic hormone, leutinising releasing hormone, enkephalin, oxycotin, parathyroid hormone, thyrotropic releasing hormone or vasopressin.

5

5. A capsule according to claim 1, wherein the active ingredient is a  $\beta$ -lactam antibiotic drug.

6. A capsule according to claim 5, wherein the  
10  $\beta$ -lactam antibiotic drug is penicillin G., ampicillin, amoxicillin, methacillin, carbenicillin, cefoxitin, cephamandole, cephaprin, cephmetazole, cephanone, oxacephalosporin, or N-formimidoyl thienamycin.

15 7. A capsule according to any one of the preceding claims, wherein the absorption promoter is an organic aromatic carboxylic acid, ester, amide or salt thereof.

8. A capsule according to claim 7, wherein the  
20 absorption promoter is salicylic acid or a salt thereof.

9. A capsule according to claim 8, wherein the  
absorption promoter is salicylic acid; 5-methoxysalicylic acid; 5-methyl salicylic acid; 3-methylsalicylic acid; 5-  
25 tert-octylsalicylic acid; 3-tert-butyl-6-methylsalicylic

acid; 3,5-diisopropylsalicylic acid; 3-tert-butyl-5-methylsalicylic acid; 5-bromosalicylic acid; 3,5-diiodosalicylic acid; 3-methoxy-salicylic acid; 5-octyloxysalicylic acid; 5-butoxysalicylic acid; 5-chlorosalicylic acid; or the sodium salt of any of the said acids.

10. A capsule according to claim 7, wherein the absorption promoter is homovanillic acid; 2,5-dihydroxybenzoic acid; 2,4-dihydroxybenzoic acid; 5-methoxy-2-hydroxy-phenylsulfonic acid; guaicol-sulfonic acid; 2-hydroxyphenylacetic acid; 2-hydroxyphenyl-methanesulfonic acid; 5-trifluoromethyl-2-hydroxybenzoic acid; 2-hydroxy-3-methoxy-benzoic acid; or the sodium salt of any of the said acids.

11. A capsule according to claim 2, 3 or 4, wherein the absorption promoter is 5-methoxysalicylic acid; salicylic acid; 2,5-dihydroxybenzoic acid; 2,4-dihydroxybenzoic acid; 3-methylsalicylic acid; 5-methylsalicylic acid; 5-tert-octylsalicylic acid; 3-tert-butyl-6-methylsalicylic acid; 3,5-diisopropylsalicylic acid; 3-tert-butyl-5-methylsalicylic acid; 5-bromosalicylic acid; 3,5-dibromosalicylic acid; 5-iodosalicylic acid; 3,5-diiodosalicylic acid; 2-hydroxy-

phenylacetic acid; 5-trifluoromethyl-2-hydroxybenzoic acid; 3-methoxysalicylic acid; 5-octyloxysalicylic acid; 5-butoxysalicylic acid; 5-chlorosalicylic acid; 2-hydroxy-3-methoxybenzoic acid; or the sodium salt of any  
5 of the said acids.

12. A capsule according to claim 5 or claim 6, wherein the absorption promoter is 5-methoxysalicylic acid; salicylic acid; homovanillic acid; 2,5-  
10 dihydroxybenzoic acid; 2,4-dihydroxybenzoic acid; 5-methoxy-2-hydroxyphenylsulfonic acid; 3-methylsalicylic acid; 5-methylsalicylic acid; 5-tert-octylsalicylic acid; 3-tert-butyl-6-methylsalicylic acid; 3,5-diisopropylsalicylic acid; 3-tert-butyl-5-methylsalicylic acid;  
15 guaicol sulfonic acid; 5-bromosalicylic acid; 3,5-dibromosalicylic acid; 5-iodosalicylic acid; 3,5-diiodosalicylic acid; 2-hydroxy-phenylacetic acid; 2-hydroxyphenylmethanesulfonic acid; 5-trifluoro-methyl-1-hydroxybenzoic acid; 3-methoxy<sup>^</sup>salicylic acid; 5-  
20 octyloxysalicylic acid; 5-butoxy-salicylic acid; 3,4-dihydroxyphenylacetic acid; 5-chlorosalicylic acid; 2-hydroxy-3-methoxybenzoic acid; salicyluric acid or the sodium salt of any of the said acids.

25 13. A capsule according to any one of claims 1 to 6,

wherein the absorption promoter is a surface active agent.

14. A capsule according to claim 13, wherein the  
5 surface active agent is a mixture of a) a higher fatty acid salt and b) a fatty alcohol or glyceride.

15. A capsule according to claim 14, wherein the  
component b) is a mono- or di-glyceride.

10

16. A compound according to claim 14, wherein the  
higher fatty acid salt is sodium laurate and the fatty alcohol or glyceride is cetyl alcohol, stearyl alcohol, glyceryl monostearate or glyceryl monocaproate.

15

17. A capsule according to any one of the preceding  
claims, wherein the pharmaceutical composition contains a  
pharmaceutically acceptable carrier.

20 18. A capsule according to claim 17, wherein the  
carrier is an oil.

19. A capsule according to claim 18, wherein the oil  
is arachis oil.

25



20. A capsule according to claim 17, wherein the carrier comprises polyethylene glycol having a molecular weight of from 400-4000.

5 21. A capsule according to any one of the preceding claims, wherein the capsule shell comprises a gelatin composition.

22. A capsule according to any one of the preceding  
10 claims, wherein the film-forming composition comprises an acrylic polymer.

23. A capsule according to claim 22, wherein the acrylic polymer is an anionic copolymer derived from  
15 acrylic or methacrylic acid and/or at least one methyl acrylate.

24. A capsule according to claim 23, wherein the acrylic polymer is a mixture of acrylic copolymers.  
20


25. A capsule according to claim 24, wherein the acrylic polymer is a mixture of two acrylic copolymers, a first said copolymer being derived from acrylic and methacrylic acid esters with a low content of quaternary  
25 ammonium groups, the molar ratio of the said quaternary

ammonium groups:the said ester groups being about 1:40,  
and having a mean molecular weight of about 150,000, and  
a second said copolymer being derived from methacrylic  
acid and methyl methacrylate, the molar ratio of free  
5 carboxyl:ester groups being about 1:2, and having a mean  
molecular weight of about 135,000, the said first and  
second copolymers being present in the mixture in a  
proportional amount of 2:3 respectively.

10 26. A capsule according to claim 24, wherein the  
acrylic polymer is a mixture of three acrylic copolymers;  
a first said copolymer being derived from acrylic and  
methacrylic acid esters with a low content of quaternary  
ammonium groups, the molar ratio of the said quaternary  
15 ammonium groups:the said ester groups being about 1:40,  
and having a mean molecular weight of about 150,000, a  
second said copolymer being derived from methacrylic acid  
and methyl methacrylate, the molar ratio of free  
carboxyl:ester groups being about 1:2, and having a mean  
20 molecular weight of about 135,000, and a third said  
copolymer being derived from methacrylic acid and methyl  
methacrylate, the molar ratio of free carboxyl:ester  
groups being about 1:1 and having a mean molecular weight  
of about 135,000, the said first, second and third  
25 copolymers being present in the mixture in a proportional

amount of 1:1:3 respectively.

27. A capsule for oral administration of a pharmaceutically active ingredient, which capsule  
5 contains a pharmaceutical composition, which composition comprises the active ingredient and an absorption promoter capable of enhancing absorption of the active ingredient from a region below the upper part of the small intestine into the bloodstream, and which capsule  
10 is coated with a film forming composition, which film is sufficiently insoluble at a pH below 7 as to be capable of protecting the capsule and its contents from the gastric and small-intestinal juices until the capsule reaches the colon, whereupon the coating and capsule are  
15 capable of eroding or dissolving so as to release the active ingredient for absorption into the bloodstream.







FIG. 2






FIG. 4

**THIS PAGE BLANK (USPTO)**